Exploring Oxygen Therapy as a Supporting Treatment for Asthma: Current Insights and Perspectives.

Asthma is a chronic inflammatory disorder of the airways affecting over 260 million people worldwide and remains a major clinical and socioeconomic challenge. Despite substantial advances in pharmacological management (including inhaled corticosteroids, β2-agonists, leukotriene receptor antagonists, and biologic therapies), many patients continue to experience uncontrolled symptoms or corticosteroid resistance. This persistent unmet need has prompted interest in adjunctive and alternative treatment strategies. Oxygen therapy during asthma exacerbations and worsening pulmonary obstruction is a standard life-saving procedure. However, various forms of oxygen therapy are being considered for long-term treatment to reduce the number of exacerbations. Experimental and preliminary clinical data indicate that oxygen therapy may offer multiple benefits, including improved oxygenation, anti-inflammatory effects, reduced oxidative stress, modulation of nitric oxide signaling, enhanced immune responses, and promotion of angiogenesis. These mechanisms may collectively alleviate airway inflammation and improve pulmonary function. Nevertheless, clinical evidence on hyperbaric oxygen therapy (HBOT) in asthma remains limited. Existing small-scale studies suggest its safety but provide inconclusive results regarding its efficacy. Potential adverse effects such as barotrauma, oxygen toxicity, and transient anxiety necessitate careful patient selection and standardized treatment protocols. Further large-scale, randomized controlled trials are required to determine the therapeutic value of HBOT and to define its role as an adjunctive therapy in the comprehensive management of asthma.